Breast Cancer
BGB-43395-302:An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors(Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease
- Details
ClinicalTrials.gov ID:
NCT07492641
Diagnosis Type:
NA
USOR Number:
- Address
,
P: